Altimmune, Inc.
ALT
$3.31
-$0.06-1.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 420.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 420.00% | 0.00% | 0.00% |
| Cost of Revenue | 3.59% | -2.17% | -6.94% | -24.46% | -18.53% |
| Gross Profit | -3.62% | 2.14% | 7.04% | 24.46% | 18.53% |
| SG&A Expenses | 33.09% | 34.36% | 106.48% | 18.82% | 1.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.91% | 7.86% | 16.28% | -15.78% | -14.29% |
| Operating Income | -10.94% | -7.88% | -16.19% | 15.78% | 14.29% |
| Income Before Tax | -3.07% | -11.39% | -18.02% | 16.77% | 10.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.07% | -15.26% | -18.02% | 16.77% | 10.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.07% | -15.26% | -18.02% | 16.77% | 10.12% |
| EBIT | -10.94% | -7.88% | -16.19% | 15.78% | 14.29% |
| EBITDA | -10.98% | -7.92% | -16.24% | 15.76% | 14.21% |
| EPS Basic | 54.71% | 30.03% | 16.42% | 33.85% | 21.76% |
| Normalized Basic EPS | 56.33% | 34.55% | 16.43% | 33.85% | 21.74% |
| EPS Diluted | 54.71% | 30.03% | 16.42% | 33.85% | 21.76% |
| Normalized Diluted EPS | 56.33% | 34.55% | 16.43% | 33.85% | 21.74% |
| Average Basic Shares Outstanding | 127.60% | 64.75% | 41.19% | 25.79% | 14.88% |
| Average Diluted Shares Outstanding | 127.60% | 64.75% | 41.19% | 25.79% | 14.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |